Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Arkansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Arkansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Arkansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Appalanaidu Sasapu (NPI 1699936252)

Field	Value
Entity Type	Individual
Organization	Appalanaidu Sasapu
Address	8901 Carti Way
City	Little Rock
State	AR
ZIP	72205
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	June 17, 2008

Payer Source	Total Paid
Medicare	$2.6M
Medicaid	$0

Key Findings

APPALANAIDU SASAPU is a Hematology & Oncology Physician with lifetime Medicare revenue of $2.6M and no Medicaid billing on file (none). The NPI was enumerated 2008-06-17 (~18 years ago), indicating an established practice with long tenure within Medicare billing.

Revenue is highly concentrated in a few infusion drugs: the top three Medicare codes (J9271, J1569, J9299) together account for 66.6% of this provider's total Medicare revenue. Individually, J9271 ($1.2M, 45.9%), J1569 ($289.8K, 11.5%), and J9299 ($230.4K, 9.2%) are the dominant revenue drivers, signaling dependence on a narrow set of high-use therapeutic injections.

The code mix and descriptions point to an infusion-focused oncology practice. High-volume use of J9271 (pembrolizumab) and J9299 (nivolumab) alongside chemotherapy administration codes (96413, 96417) and multiple infusion administration codes (96365, 96375, 96367) suggests the operation centers on outpatient infusions and immune-oncology treatment regimens rather than predominantly clinic-only management.

Competitive standing for the top biologics is mixed: J9271 ranks #182 of 1841 providers nationally (90th percentile; typical, unremarkable volume for this code), and J1569 ranks #75 of 542 providers nationally (86th percentile; typical, unremarkable volume for this code), indicating broadly strong but not dominant usage of pembrolizumab and IVIG relative to peers. By contrast, J9299 ranks #363 of 505 providers nationally (28th percentile; typical, unremarkable volume for this code), implying comparatively modest nivolumab use versus the national cohort.

Several service codes are statistical outliers on the national distribution, highlighting operational intensity in complex visits and infusion throughput. 99215 is listed as an extreme outlier (ranks #2438 of 145531 providers nationally, 98th percentile), and 96375 is also an extreme outlier (ranks #64 of 5191 providers nationally, 99th percentile); additionally, 96413 is characterized as notably above typical national volume (ranks #227 of 7514 providers nationally, 97th percentile). Together these suggest a high rate of complex evaluation-and-management encounters combined with very high infusion activity.

Supportive care and ancillary services appear as routine components of the practice: denosumab (J0897, $214.3K, 8.5%), ferric derisomaltose (J1437, $117.3K, 4.7%), epoetin alfa (J0885, $64K, 2.5%), and lab panels/CBC codes (80053, 85025, 36415) are all present. This mix is consistent with oncology clinics that provide bone health, anemia management, iron repletion, and on-site phlebotomy and lab testing to support systemic therapy.

The absence of Medicaid billing (none) makes this provider effectively single-payer in scope, relying on Medicare for the full reported lifetime revenue of $2.6M. Analysts should note this payer concentration when assessing revenue stability or access patterns, as the practice has limited documented exposure to Medicaid populations which could reflect site-of-service, network participation, or patient panel composition.

Operationally, the combination of very high-volume infusion codes and high-complexity E/M levels suggests workforce and throughput capacity focused on infusion chair time and complex visit management. Given the practice's long tenure (NPI enumerated 2008-06-17 (~18 years ago)) and concentrated revenue mix, payers and provider analysts may want to review referral flows, site-of-service billing, and network alignment to understand scalability and payer negotiation posture.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

84 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	26,800	$40	$1.2M
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	8,050	$40	$289.8K
J9299	Injection, nivolumab, 1 mg	9,600	$20	$230.4K
J0897	Injection, denosumab, 1 mg	11,280	$20	$214.3K
J1437	Injection, ferric derisomaltose, 10 mg	6,900	$20	$117.3K
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	2,630	$40	$92K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	740	$90	$64.1K
J0885	Injection, epoetin alfa, (for non-esrd use), 1000 units	10,670	$10	$64K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	680	$80	$56.9K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	450	$120	$55.8K

Showing 1–10 of 84

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 84 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Arkansas Distribution

Appalanaidu Sasapu — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Arkansas

Full comparison — all codes billed, vs. state median

84 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	9	40	20,700	$40	$896.3K
J9299	24	30	15,660	$20	$432.9K
J1569	2	10	2,560	$40	$120.3K
J1437	11	20	6,450	$20	$107.8K
Q5115	13	20	2,800	$30	$95.9K
J0897	17	160	2,580	$20	$89.7K
J0885	10	40	4,070	$10	$38K
96413	16	80	380	$90	$36.6K
J9217	32	50	100	$130	$20K
99214	446	4,300	130	$70	$18.8K

Showing 1–10 of 84

Related Providers

Other providers that share a Tax Identification Number (TIN) with Appalanaidu Sasapu, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Central Arkansas Radiation Therapy Institute Inc	AR	Hematology & Oncology Physician	$0	$11M
Central Arkansas Radiation Therapy Institute Inc	AR	Radiation Oncology Physician	$6.7M	$3.6M
Kamal Patel	AR	Hematology & Oncology Physician	$5.7M	$0
Ryan Hall	AR	Hematology & Oncology Physician	$4.6M	$0
Balagopalan Nair	AR	Hematology & Oncology Physician	$4.1M	$0
Lawrence Mendelsohn	AR	Hematology & Oncology Physician	$3.4M	$0
Jamie Burton	AR	Hematology & Oncology Physician	$2.8M	$0
Kewen Jauss	AR	Hematology & Oncology Physician	$2.8M	$0
Mariann Harrington	AR	Hematology & Oncology Physician	$2.7M	$0
Derek Middleton	AR	Hematology & Oncology Physician	$2.5M	$0

Nearby Providers

Other providers in the same ZIP code as Appalanaidu Sasapu, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
University Of Arkansas For Medical Sciences	AR	General Acute Care Hospital	$0	$87.2M
University Of Arkansas For Medical Sciences	AR	Internal Medicine Physician	$0	$28.6M
University Of Arkansas For Medical Sciences	AR	Pediatrics Physician	$0	$27.6M
Arkansas Department Of Health Immunizations	AR	Public Health or Welfare Agency	$0	$19.3M
Baptist Health	AR	General Acute Care Hospital	$0	$16.4M
Arkansas Department Of Health Family Planning Clinic	AR	Public Health or Welfare Agency	$0	$15.6M
Pediatrix Medical Group Of Arkansas PA	AR	Neonatal-Perinatal Medicine Physician	$0	$14.6M
Chenal Family Therapy, Plc	AR	Mental Health Counselor	$0	$12.2M
Francis A. Allen School For Exceptional Children, Inc.	AR	Developmentally Disabled Services Day Training Agency	$0	$11.9M
Arkansas Department Of Health Std	AR	Public Health or Welfare Agency	$0	$8.4M

Appalanaidu Sasapu — Billing Profile & Reimbursement Data

Sign up for Appalanaidu Sasapu — Billing Profile & Reimbursement Data policy alerts

Appalanaidu Sasapu — Billing Profile & Reimbursement Data

Sign up for Appalanaidu Sasapu — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References